⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RZLT News
Rezolute, Inc. Common Stock (NV)
Form 8-K
sec.gov
RZLT
Form 8-K
sec.gov
RZLT
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
globenewswire.com
RZLT
Form 8-K
sec.gov
RZLT
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
globenewswire.com
RZLT
Form 8-K
sec.gov
RZLT
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
globenewswire.com
RZLT
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
globenewswire.com
RZLT
Rezolute to Participate in Upcoming Investor Conferences
globenewswire.com
RZLT
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
globenewswire.com
RZLT